Aspen Neuroscience is a biotech startup that is pursuing the development of best-in-class autologous cell therapies for neurological diseases beginning with Parkinson disease and extending across the brain and other affected organs. More info can be found
Location: United States, California, La Jolla
Employees: 51-200
Phone: +1 858-263-1222
Total raised: $379M
Founded date: 2018
Investors 11
Show more
Funding Rounds 5
| Date | Series | Amount | Investors |
| 21.11.2025 | Series C | $115M | - |
| 24.12.2022 | - | $40M | - |
| 10.05.2022 | Series B | $147.5M | - |
| 14.04.2020 | Series A | $70M | - |
| 12.12.2019 | Seed | $6.5M | - |
Mentions in press and media 26
| Date | Title | Description |
| 21.11.2025 | Aspen Neuroscience: $115 Million Series C Raised To Advance Personalized Cell Therapy Pipeline | Aspen Neuroscience has closed a $115 million Series C financing round to accelerate clinical development of its personalized autologous cell therapy programs, marking one of the company’s most significant funding milestones to date. The San... |
| 20.11.2025 | Aspen Neuroscience Raises $115M in Series C Funding | Aspen Neurosciences, a San Diego, CA-based clinical-stage biotechnology company pioneering autologous regenerative therapies, raised $115M in Series C funding. The round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, a... |
| 24.12.2022 | Aspen Neuroscience Receives $40M in Debt Financing From Silicon Valley Bank | Aspen Neuroscience, a San Diego, CA-based private biotechnology company developing autologous cell therapies including an iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), received $40M in Debt Financing. Si... |
| 09.09.2022 | Meet John Prufeta, General Partner of Medical Excellence Capital | MEC invests in cell therapy, gene therapy, regenerative medicine, synthetic biology, and AI Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there ... |
| 16.05.2022 | Digital health news, funding roundup in the prior week; May 16, 2022 | $3.1B to fight COVID globally; Academy partnered with Nuance; Vida launched prescription service Top Health News Vida Health, which provides a collaborative care model that provides access to practitioners including coaches, licensed therap... |
| 10.05.2022 | Aspen Neuroscience raises $147.5M | Aspen Neuroscience has raised a $147.5 million Series B co-led by GV, LYFE Capital and Revelation Partners. San Diego-based Aspen is developing cell replacement therapies designed to target neurodegenerative diseases such as Parkinson's dis... |
| 09.05.2022 | San Diego’s Aspen Neuroscience lands $147M for Parkinson’s cell therapy | Aspen Neuroscience, a San Diego biotech that’s developing cell replacement therapy to treat Parkinson’s disease, has raised $147.5 million in a second round of venture capital funding. The investment brings the total amount raised by Aspen,... |
| 09.05.2022 | Aspen Neuroscience Scores $147.5M More | San Diego-based biotech startup Aspen Neuroscience said this morning that it has raised $147.5M in a Series B funding round. The company--which is working on treatments for Parkinson's disease--said the funding was co-led by GV, LYFE Capita... |
| 09.05.2022 | Aspen Neuroscience Raises $147.5M in Series B Financing | Damien McDevitt, PhD, president and CEO of Aspen Neuroscience, Inc. Aspen Neuroscience, Inc., a San Diego, CA-based private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron repla... |
| 09.05.2022 | Investors take root in Aspen Neuroscience's customized cell therapy as $147.5M round closes | Aspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company's series B with $147.5 million following an initial $70 million round two year... |
Show more